ATHE
Income statement / Annual
Last year (2024), Alterity Therapeutics Limited's total revenue was $4.02 M,
an increase of 2.63% from the previous year.
In 2024, Alterity Therapeutics Limited's net income was -$19.12 M.
See Alterity Therapeutics Limited,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
06/30/2024 |
06/30/2023 |
06/30/2022 |
06/30/2021 |
06/30/2020 |
06/30/2019 |
06/30/2018 |
06/30/2017 |
06/30/2016 |
06/30/2015 |
| Operating Revenue |
$4.02 M |
$3.92 M |
$5.12 M |
$4.34 M |
$0.00 |
$108.54 K |
$201.17 K |
$132.40 K |
$142.66 K |
$176.84 K |
| Cost of Revenue |
$214.30 K
|
$285.07 K
|
$364.67 K
|
$360.03 K
|
$112.43 K
|
$29.70 K
|
$21.80 K
|
$21.33 K
|
$22.81 K
|
$257.30 K
|
| Gross Profit |
$3.80 M
|
$3.63 M
|
$4.76 M
|
$3.98 M
|
-$112.43 K
|
$78.84 K
|
$179.38 K
|
$111.07 K
|
$119.85 K
|
-$80.46 K
|
| Gross Profit Ratio |
0.95
|
0.93
|
0.93
|
0.92
|
0
|
0.73
|
0.89
|
0.84
|
0.84
|
-0.45
|
| Research and Development Expenses |
$18.64 M
|
$13.20 M
|
$14.75 M
|
$12.28 M
|
$10.10 M
|
$12.98 M
|
$6.70 M
|
$5.70 M
|
$9.59 M
|
$12.30 M
|
| General & Administrative Expenses |
$4.77 M
|
$4.99 M
|
$5.43 M
|
$6.85 M
|
$3.33 M
|
$4.28 M
|
$4.32 M
|
$3.95 M
|
$3.59 M
|
$4.06 M
|
| Selling & Marketing Expenses |
-$9.67 K
|
$51.48 K
|
$79.33 K
|
$21.81 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$87.85 K
|
| Selling, General & Administrative Expenses |
$4.76 M
|
$5.04 M
|
$5.51 M
|
$6.87 M
|
$3.33 M
|
$4.28 M
|
$4.32 M
|
$3.95 M
|
$3.59 M
|
$4.15 M
|
| Other Expenses |
$0.00
|
-$282.96 K
|
-$364.67 K
|
$0.00
|
-$3.36 M
|
-$4.79 M
|
$0.00
|
-$241.89 K
|
-$241.95 K
|
-$170.98 K
|
| Operating Expenses |
$23.41 M
|
$17.35 M
|
$17.54 M
|
$19.31 M
|
$10.07 M
|
$12.47 M
|
$11.10 M
|
$6.77 M
|
$8.49 M
|
$10.61 M
|
| Cost And Expenses |
$23.62 M
|
$17.63 M
|
$17.90 M
|
$19.67 M
|
$10.07 M
|
$12.47 M
|
$11.10 M
|
$6.77 M
|
$8.49 M
|
$10.61 M
|
| Interest Income |
$268.42 K
|
$16.44 K
|
$2.50 K
|
$20.68 K
|
$17.12 K
|
$108.54 K
|
$201.17 K
|
$132.40 K
|
$142.66 K
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$147.53 K
|
$102.26 K
|
$54.21 K
|
$75.37 K
|
$112.43 K
|
$29.70 K
|
$21.80 K
|
$21.33 K
|
$22.81 K
|
$31.59 K
|
| EBITDA |
-$19.57 M |
-$17.51 M |
-$17.39 M |
-$19.36 M |
-$13.34 M |
-$12.77 M |
-$11.37 M |
-$6.86 M |
-$8.56 M |
-$10.57 M |
| EBITDA Ratio |
-4.87
|
-4.47
|
-3.39
|
-4.46
|
0
|
-117.62
|
-56.52
|
-51.82
|
-60.03
|
-59.8
|
| Operating Income Ratio |
-4.88
|
-3.74
|
-3.03
|
-3.5
|
0
|
-117.14
|
-38.62
|
-51.98
|
-60.19
|
-59.01
|
| Total Other Income/Expenses Net |
$524.33 K
|
$904.68 K
|
$2.72 M
|
-$133.04 K
|
$428.68 K
|
$324.64 K
|
-$127.86 K
|
-$786.28 K
|
$811.97 K
|
$4.68 M
|
| Income Before Tax |
-$19.08 M
|
-$13.70 M
|
-$12.78 M
|
-$15.31 M
|
-$10.06 M
|
-$12.34 M
|
-$8.27 M
|
-$7.54 M
|
-$7.73 M
|
-$5.89 M
|
| Income Before Tax Ratio |
-4.75
|
-3.5
|
-2.49
|
-3.53
|
0
|
-113.67
|
-41.09
|
-56.97
|
-54.18
|
-33.28
|
| Income Tax Expense |
$46.09 K
|
$104.46 K
|
$70.01 K
|
$0.00
|
-$362.19 K
|
-$376.03 K
|
-$495.44 K
|
$660.21 K
|
$0.00
|
-$170.98 K
|
| Net Income |
-$19.12 M
|
-$13.81 M
|
-$12.85 M
|
-$15.31 M
|
-$9.70 M
|
-$11.96 M
|
-$8.27 M
|
-$7.54 M
|
-$7.73 M
|
-$5.89 M
|
| Net Income Ratio |
-4.76
|
-3.53
|
-2.51
|
-3.53
|
0
|
-110.21
|
-41.09
|
-56.97
|
-54.18
|
-33.28
|
| EPS |
-3.12 |
-3.42 |
-3.18 |
-5.4 |
-6.48 |
-11.64 |
-9.3 |
-8.46 |
-8.7 |
-7.02 |
| EPS Diluted |
-3.12 |
-3.42 |
-3.18 |
-5.4 |
-6.48 |
-11.64 |
-9.3 |
-8.46 |
-8.7 |
-7.02 |
| Weighted Average Shares Out |
$6.08 M
|
$4.05 M
|
$4.01 M
|
$2.83 M
|
$1.49 M
|
$1.03 M
|
$888.79 K
|
$889.82 K
|
$888.52 K
|
$837.86 K
|
| Weighted Average Shares Out Diluted |
$6.08 M
|
$4.05 M
|
$4.01 M
|
$2.83 M
|
$1.49 M
|
$1.03 M
|
$889.82 K
|
$889.82 K
|
$889.82 K
|
$837.86 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
